U.S. troops given anti-malaria drug despite concern of side effects 04:33. WASHINGTON --When Jimmy Corrigan left on deployment in the Navy three years ago, he was in the best physical shape of his ...

Anyone who’s ever taken the antimalarial drug Mefloquine will tell you about the dreams. I was back in Haditha, Iraq, where Wimberg was killed. I was in the alleyway between the two buildings re ...

The top doctor for Green Berets and other elite Army commandos has told troops to immediately stop taking mefloquine, an anti-malaria drug found to cause permanent brain damage in rare cases .

Mefloquine was approved for use by the U.S. Food and Drug Administration (FDA) in 1989. Then, in 2013, the FDA published a safety alert about the drug and placed a black box warning on the drug label.

Early the morning of March 11, 2012, Army staff sergeant Robert Bales left his remote outpost in an impoverished region of Kandahar Province, Afghanistan and killed 16 people in two nearby villages.

The Peace Corps takes the risk of side effects from mefloquine, or any medication, very seriously. The Peace Corps does not provide mefloquine to Volunteers for whom it is medically ...

Since the late 1980s, the drug mefloquine, sold under the brand name Lariam, was dispensed to service members, Peace Corps volunteers and other world travelers. The military now uses it only as a ...

Objective: To compare the efficacy and tolerability of mefloquine and proguanil in malaria prophylaxis in sickle cell anaemia. Design: Nonblind, prospective, multicentre study. Participants: The ...

Early 2020 saw the world break into what has been described as a "war-like situation": A pandemic, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the likes of ...

Researchers from LSTM Cochrane Infectious Diseases Group publish two systematic reviews this week about the safety of mefloquine (Lariam) for preventing malaria in travellers.

Pyronaridine–artesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical and parasitologic response in the per-protocol population on day 28, corrected ...